-
Mashup Score: 12
ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
Source: www.redjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 61
The POP-RT phase III randomized trial showed improved biochemical failure-free survival and metastasis-free survival with whole pelvic radiotherapy (WPRT) versus prostate-only radiotherapy (PORT) for high/very high-risk prostate cancer, albeit with worse RTOG late urinary toxicity. We report updated late urinary adverse effects and bladder dose-effect relations within this trial.
Source: www.redjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 24
Patients’ understanding of radiotherapy (RT) and data regarding optimal approaches to patient education (PE) within radiation oncology (RO) are limited. We aimed to evaluate PE practices of radiation oncologists and interprofessional RT care team members to inform recommendations for delivering inclusive and accessible PE.
Source: www.redjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Current Issue Table of Contents: International Journal of Radiation Oncology, Biology, Physics - 1 month(s) ago
ASTRO Member s, full access to the journal is a member benefit. Use your society credentials to access all journal content and features. Edited by Salma Jabbour MD, Sue Yom
Source: www.redjournal.orgCategories: General Medicine News, Onc News and JournalsTweet-
New #RedJournal special issue: Combinatorial Therapies edited by Salma Jabbour, MD, FASTRO, & Sue Yom, MD, PhD, FASTRO. This special edition explores imaging, systematic radiosensitization, integrating targeted therapy with radiation & more. https://t.co/PnijX6SnFB… https://t.co/a3WHw1TU4h https://t.co/TUQpdPj1g3
-
-
Mashup Score: 21ASTRO Gold Medal Award Recipient - 2 month(s) ago
C. Norman Coleman, M.D.
Source: www.redjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Overview of Biosimilars in Inflammatory Bowel Diseases : Official journal of the American College of Gastroenterology | ACG - 2 month(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 22
Reirradiation is increasingly used in children and adolescents/young adults (AYA) with recurrent primary central nervous system tumors. The Pediatric Normal Tissue Effects in the Clinic (PENTEC) reirradiation task force aimed to quantify risks of brain and brain stem necrosis after reirradiation.
Source: www.redjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 44
Radiation-associated angiosarcoma of the breast (RAASB) is a rare side effect following breast conserving therapy (BCT) and has been associated with poor outcomes. At this time, there is no consensus regarding management of RAASB and the role of reirradiation remains controversial. We present our modern institutional outcomes in managing RAASB with incorporation of neoadjuvant hyperfractionated reirradiation.
Source: www.redjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 22
Erectile dysfunction (ED) is a common side effect after prostate cancer stereotactic body radiotherapy (SBRT). We aimed to assess the correlation between the dose to the penile bulb (PB), internal pudendal arteries (IPA), and crura with the development of ED after ultra-hypofractionation as part of a phase II clinical trial of urethra-sparing prostate SBRT.
Source: www.redjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 52Long term results of a phase I dose escalation trial of ablative stereotactic body radiation therapy - 3 month(s) ago
Stereotactic body radiation therapy (SBRT) is increasingly used for oligometastatic disease as well as palliation, but treatment protocols for non-spine bone and nodal metastases are lacking, with a wide variety of schedules applied. Therefore, a prospective dose-escalation trial was initiated, involving 90 patients, among whom 52 (58%) had primary prostate tumors, 13 had breast tumors (14%), and 25 (28%) had other primary tumor types. All visible lymph node and/or non-spine bone oligometastases were treated in three consecutive cohorts: 5×7.0 Gy, 3×10.0 Gy, or 1×20.0 Gy.
Source: www.redjournal.orgCategories: General Medicine News, Onc News and JournalsTweet-
From @carole_mercier_ @piet_ost @ines_joye in #RedJournal: 90 patients with OMD were treated with SBRT to either 5x7, 3x10 or 1x20 Gy (DESTROY trial update). No late grade ≥3 toxicity & excellent LC at 4 years. Single-fraction SBRT was feasible and safe https://t.co/VlWxnayLpB https://t.co/FMkBjmPRMW
-
The #RedJournal is always looking for submissions of art and photography for our journal covers. Check out some of our '24 covers here from Daniel J. Ma, Marije Notenboom, Jennifer R. Bellon, and Jayden Rae Gracie, respectively. See our cover gallery here: https://t.co/ANcANgc4Qp https://t.co/puCoLvtPep